Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CC-93538 in Japanese adults and adolescents with eosinophilic gastroenteritis
jRCT2021210067Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic enteritis (EoN) comparing CC-93538 with Placebo (2 arms). Primary endpoint: Change in mean peak eosinophil count per high-power field in gastrointestinal biopsies from baseline to Week 16. Started Mar 2022; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic enteritis (EoN)
Beyond the preview
Go deeper on jRCT2021210067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210067.